



November 24, 2022

✓

Department of Corporate Services,  
P. J. Towers, Dalal Street,  
Mumbai Samachar Marg,

---

Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (East),

---

---

We would like to inform you that the U.S. FDA inspected Lupin's Mandideep Unit-1 facility from November 14, 2022 to November 23, 2022. The inspection of the facility closed with issuance of a Form-483 with eight observations each for the Drug Product facility and API facility at the site.

We are committed to addressing the observations and will work with the U.S. FDA to resolve these issues at the earliest. We uphold quality and compliance issues with utmost importance and remain committed to be compliant with cGMP quality standards across all our facilities.

This may kindly be considered as a disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you,

For **LUPIN LIMITED**

**R. V. SATAM**  
**COMPANY SECRETARY**  
**(ACS-11973)**